484 related articles for article (PubMed ID: 15545169)
1. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
[TBL] [Abstract][Full Text] [Related]
3. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
[TBL] [Abstract][Full Text] [Related]
4. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
5. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Banerjee S; Bishop WP
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
[TBL] [Abstract][Full Text] [Related]
6. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
10. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
12. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
14. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
15. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis.
Nguyen TM; Daubard M; Le Gall C; Larger M; Lachaux A; Boulieu R
Ther Drug Monit; 2010 Aug; 32(4):433-7. PubMed ID: 20479703
[TBL] [Abstract][Full Text] [Related]
17. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
18. Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease.
Vikingsson S; Andersson D; Almer S; Peterson C; Hindorf U
J Crohns Colitis; 2014 Dec; 8(12):1702-9. PubMed ID: 25239576
[TBL] [Abstract][Full Text] [Related]
19. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
Seidman EG
Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
